Any salt or ester of glycerophosphoric acid.
DrugDrug NameDrug Indication
DB02261Platelet Activating FactorNot Available
DB03438LysophosphatidylglycerolNot Available
DB04327PhosphatidylethanolamineNot Available
DB04660Choline alfoscerateNot Available
DB04897LucinactantIntended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
DB05456ETC-588Investigated for use/treatment in atherosclerosis, coronary artery disease, and vascular diseases.
DB09114Colfosceril palmitateColfosceril palmitate is indicated for the treatment of respiratory distress syndrome (RDS) in premature infants. The official label is referred as a intratracheal suspension for prophylactic treatment of infants of less than 1350 grams of birth weight under risk of developing RDS, or in infants with birth weight greater than 1350 grams with pulmonary immaturity, or as rescue treatment of infants that already developed RDS.[L1109] The central feature of RDS is a surfactant deficiency due to lung immaturity. This lung condition is more frequently presented due to risk factors like prematurity, delayed lung maturation caused by maternal diabetes or male gender, or surfactant dysfuntion due to perinatal asphyxia, pulmonary infection or delivery without labor.[T70]
DB11283DL-dimyristoylphosphatidylcholineDL-dimyristoylphosphatidylcholine is not an active pharmaceutical agent and has no indication.
DB11284DL-dimyristoylphosphatidylglycerolDL-dimyristoylphosphatidylglycerol is not an considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indications.
DB13615MifamurtideIndicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy [L1203].
DB140991,2-DistearoyllecithinNot Available